KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Leases (2019 - 2023)

Vir Biotechnology (VIR) has disclosed Current Leases for 4 consecutive years, with $7.3 million as the latest value for Q1 2023.

  • Quarterly Current Leases changed N/A to $7.3 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Mar 2023, changed N/A year-over-year, with the annual reading at $4.1 million for FY2022, N/A changed from the prior year.
  • Current Leases hit $7.3 million in Q1 2023 for Vir Biotechnology, up from $4.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.3 million in Q1 2023 to a low of $200000.0 in Q1 2020.
  • Historically, Current Leases has averaged $1.8 million across 4 years, with a median of $300000.0 in 2020.
  • Biggest YoY gain for Current Leases was 26.58% in 2020; the steepest drop was 26.58% in 2020.
  • Year by year, Current Leases stood at $237000.0 in 2019, then rose by 26.58% to $300000.0 in 2020, then soared by 1279.0% to $4.1 million in 2022, then skyrocketed by 75.68% to $7.3 million in 2023.
  • Business Quant data shows Current Leases for VIR at $7.3 million in Q1 2023, $4.1 million in Q4 2022, and $300000.0 in Q4 2020.